Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03237923 · ClinicalTrials.gov registry record
Evaluation of the EasySense System in Congestive Heart Failure
A clinical trial of Congestive Heart Failure, sponsored by Ohio State University.
- Completed
- Registry status
- 47
- Enrollment target
- 1
- Study location
NCT03237923: Completed study of Congestive Heart Failure, sponsored by Ohio State University.
NCT03237923 is a study of Congestive Heart Failure that has completed, run by Ohio State University. The registered enrollment target is 47 participants, below the 329-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03237923, a study of Congestive Heart Failure, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The EasySense device is a non-invasive device designed to measure lung fluid in patients with Congestive Heart Failure (CHF). This study seeks to evaluate the efficacy of the EasySense system in measuring lung fluid volume.
Primary Outcome
Patient volume status extracted from medical records will be compared to what the EasySense device measures.
Conditions Studied
Interventions
- DEVICE EasySense device
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2020-06-30 |
What the finished NCT03237923 record still lists
NCT03237923 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 329-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which EasySense device is the first listed.
NCT03237923 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03237923 about?
NCT03237923 is a clinical study titled "Evaluation of the EasySense System in Congestive Heart Failure". The EasySense device is a non-invasive device designed to measure lung fluid in patients with Congestive Heart Failure (CHF). This study seeks to evaluate the efficacy of the EasySense system in measuring lung fluid volume.
What is the current status of trial NCT03237923?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2017-07-01. Estimated completion is 2020-06-30.
What conditions does trial NCT03237923 study?
This clinical trial studies the following conditions: Congestive Heart Failure.
What interventions are being tested in trial NCT03237923?
The interventions under investigation include: EasySense device (DEVICE).
Who is sponsoring clinical trial NCT03237923?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03237923 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congestive Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03237923's enrollment target sits among peer trials
47 37th of 51 higher than 15 of 51 other Congestive Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congestive Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Palliative Care for People With HF
RECRUITING
-
Circulating Markers for Ischemic Heart Disease
RECRUITING
-
Stress and Congestive Heart Failure
RECRUITING · NA
-
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
RECRUITING · NA
-
Care Transitions App for Patients With Multiple Chronic Conditions
RECRUITING · NA
-
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI